A Bacterial Lifestyle Switch Provides Antibiotic Resistance
|
By LabMedica International staff writers Posted on 06 Jan 2016 |

Image: Light micrograph of Bacillus cereus in a small colony variant (SCV) (Photo courtesy of Markus Kranzler/Vetmeduni Vienna).
Researchers have reported for the first time that following contact with certain antibiotics the pathogenic Bacillus cereus can switch into a special slowed-down mode and form small colony variants (SVCs) that are difficult to diagnose and almost impossible to treat with certain antibiotics.
Bacillus cereus causes vomiting and diarrhea as well as systemic and local infections such as sepsis or eye infections. The newly discovered mechanism, from a study led by researchers from the Vetmeduni Vienna (University of Veterinary Medicine Vienna (Austria), provides an explanation for this and possibly other cases of antibiotic resistance.
B. cereus had so far been considered to be exclusively endospore-forming in response to harsh conditions. The new study discovered an alternative lifestyle in which B. cereus forms SCVs in response to exposure to aminoglycoside antibiotics. The B. cereus SCVs grow slower, have an altered metabolism, and provide resistance to aminoglycosides. “The bacterium protects itself against the harmful effects of the antibiotics by forming these SCVs. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance,” explained first author Dr. Frenzel.
The discovery of this mechanism is of great significance for clinical practice and will require rethinking diagnostics and therapy. Traditional diagnostics are based on identification of metabolic features of B. cereus, but these tests do not detect SCVs. This may result in incorrect antibiotic therapies or even failed diagnoses. Molecular tests may be the only way to diagnose this form of B. cereus. Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. “In this case, a combination therapy with other antibiotic groups is advisable,” Dr. Frenzel recommends.
Another bacterium, Staphylococcus aureus, also forms SCVs, but is capable of reverting to its original state. For B. cereus, the SCV form appears to be final, suggesting a new mechanism. “We believe that the SCV formation in B. cereus functions differently than in S. aureus,” said coauthor Dr. Ehling-Schulz.
“The ability to form SCVs appears to be of environmental significance for the bacteria,” said Dr. Frenzel, “B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria.”
The study, by Frenzel E, Kranzler M et al., was published December 8, 2015, in the journal mBio.
Related Links:
University of Veterinary Medicine Vienna
Bacillus cereus causes vomiting and diarrhea as well as systemic and local infections such as sepsis or eye infections. The newly discovered mechanism, from a study led by researchers from the Vetmeduni Vienna (University of Veterinary Medicine Vienna (Austria), provides an explanation for this and possibly other cases of antibiotic resistance.
B. cereus had so far been considered to be exclusively endospore-forming in response to harsh conditions. The new study discovered an alternative lifestyle in which B. cereus forms SCVs in response to exposure to aminoglycoside antibiotics. The B. cereus SCVs grow slower, have an altered metabolism, and provide resistance to aminoglycosides. “The bacterium protects itself against the harmful effects of the antibiotics by forming these SCVs. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance,” explained first author Dr. Frenzel.
The discovery of this mechanism is of great significance for clinical practice and will require rethinking diagnostics and therapy. Traditional diagnostics are based on identification of metabolic features of B. cereus, but these tests do not detect SCVs. This may result in incorrect antibiotic therapies or even failed diagnoses. Molecular tests may be the only way to diagnose this form of B. cereus. Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. “In this case, a combination therapy with other antibiotic groups is advisable,” Dr. Frenzel recommends.
Another bacterium, Staphylococcus aureus, also forms SCVs, but is capable of reverting to its original state. For B. cereus, the SCV form appears to be final, suggesting a new mechanism. “We believe that the SCV formation in B. cereus functions differently than in S. aureus,” said coauthor Dr. Ehling-Schulz.
“The ability to form SCVs appears to be of environmental significance for the bacteria,” said Dr. Frenzel, “B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria.”
The study, by Frenzel E, Kranzler M et al., was published December 8, 2015, in the journal mBio.
Related Links:
University of Veterinary Medicine Vienna
Latest Microbiology News
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








